Title : Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3β signaling axis in hepatocellular carcinoma cells.

Pub. Date : 2021 Aug 1

PMID : 33735117






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3beta signaling axis in hepatocellular carcinoma cells. Sorafenib glycogen synthase kinase 3 alpha Homo sapiens
2 In addition, vinpocetine plus sorafenib activates glycogen synthase kinase 3beta (GSK-3beta) and subsequently inhibits cytoprotective autophagy induced by vinpocetine in HCC cells. Sorafenib glycogen synthase kinase 3 alpha Homo sapiens
3 Meanwhile, overexpression of GSK-3beta was efficient to increase the apoptosis induced by vinpocetine plus sorafenib in HCC cells. Sorafenib glycogen synthase kinase 3 alpha Homo sapiens
4 Our study revealed that vinpocetine plus sorafenib could suppress the cytoprotective autophagy induced by vinpocetine and subsequently show synergistically anti-HCC activity via activating GSK-3beta and the combination of vinpocetine and sorafenib might reverse sorafenib resistance via the PI3K/protein kinase B/GSK-3beta signaling axis. Sorafenib glycogen synthase kinase 3 alpha Homo sapiens
5 Our study revealed that vinpocetine plus sorafenib could suppress the cytoprotective autophagy induced by vinpocetine and subsequently show synergistically anti-HCC activity via activating GSK-3beta and the combination of vinpocetine and sorafenib might reverse sorafenib resistance via the PI3K/protein kinase B/GSK-3beta signaling axis. Sorafenib glycogen synthase kinase 3 alpha Homo sapiens